The transaction is expected to be completed by September 30, 2021
GlaxoSmithKline Pharmaceuticals (GSK) said its board has approved the sale of its manufacturing facility located at Vemgal in Karnataka to Hetero Labs for a consideration of Rs 180 crore.
The board of directors at its meeting held “approved the sale of the company’s business undertaking i.e, manufacturing facility together with the land, plant and machinery, assets, software and equipment located at Vemgal, Karnataka, to Hetero Labs,” the company said in a regulatory filing.
The transaction is expected to be completed by September 30, 2021, it added.
Consideration received from the sale is Rs 180 crore, the filing said.
PTI
Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.
